HepC Therapeutics Inc. is focused on unmet medical needs such as providing functional cure for chronic hepatitis B virus (HBV) patients who require life-long direct acting antiviral (DAA) drug therapy, treatment of hepatitis C virus (HCV) infected patients who have silent HBV coinfection without reactivation of HBV, adjuvant treatment of hepatitis (HBV or HCV) in hepatocellular cancer patients with fragile liver function. Furthermore, the SIT platform technology could mitigate symptoms of early COVID-19 patients and may contribute to a worldwide pandemic preparedness, which will be much needed in the future. The clinically validated SIT platform technology is simple to manufacture and administer, and will be affordable even in resource limited settings. Treating COVID-19 patients early in an out-patient setting would speed their recovery, reduce the likelihood that they develop severe outcomes thus prevent hospitalization and reduce demand on the healthcare system.
SIT was positively evaluated by the German Paul Ehrlich Institute (PEI)1 and the US National Institutes of Health (NIH) COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership2.